US 12,139,532 B2
Anti-human vista antibodies and use thereof
Jay Rothstein, Norwich, VT (US); Isabelle Lemercier, Enfield, NH (US); Linda Snyder, Pottstown, PA (US); and Gordon Powers, Malvern, PA (US)
Assigned to ImmuNext, Inc., Lebanon, NJ (US); and THE TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed by ImmuNext, Inc., Lebanon, NH (US); and THE TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed on Apr. 17, 2017, as Appl. No. 15/489,254.
Application 15/489,254 is a continuation of application No. PCT/US2017/027800, filed on Apr. 14, 2017.
Claims priority of provisional application 62/425,184, filed on Nov. 22, 2016.
Claims priority of provisional application 62/406,632, filed on Oct. 11, 2016.
Claims priority of provisional application 62/385,871, filed on Sep. 9, 2016.
Claims priority of provisional application 62/385,893, filed on Sep. 9, 2016.
Claims priority of provisional application 62/385,805, filed on Sep. 9, 2016.
Claims priority of provisional application 62/385,785, filed on Sep. 9, 2016.
Claims priority of provisional application 62/385,627, filed on Sep. 9, 2016.
Claims priority of provisional application 62/385,888, filed on Sep. 9, 2016.
Claims priority of provisional application 62/372,362, filed on Aug. 9, 2016.
Claims priority of provisional application 62/365,081, filed on Jul. 21, 2016.
Claims priority of provisional application 62/365,087, filed on Jul. 21, 2016.
Claims priority of provisional application 62/365,102, filed on Jul. 21, 2016.
Claims priority of provisional application 62/365,085, filed on Jul. 21, 2016.
Claims priority of provisional application 62/365,166, filed on Jul. 21, 2016.
Claims priority of provisional application 62/363,929, filed on Jul. 19, 2016.
Claims priority of provisional application 62/363,925, filed on Jul. 19, 2016.
Claims priority of provisional application 62/363,931, filed on Jul. 19, 2016.
Claims priority of provisional application 62/364,073, filed on Jul. 19, 2016.
Claims priority of provisional application 62/363,917, filed on Jul. 19, 2016.
Claims priority of provisional application 62/343,355, filed on May 31, 2016.
Claims priority of provisional application 62/323,193, filed on Apr. 15, 2016.
Prior Publication US 2017/0306024 A1, Oct. 26, 2017
Int. Cl. C07K 16/28 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 1/16 (2006.01); A61P 13/12 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 37/06 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 38/17 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 1/16 (2018.01); A61P 13/12 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 37/06 (2018.01); C07K 16/2827 (2013.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
 
1. A method of treating lupus comprising administering to a patient in need thereof a therapeutically effective amount of an isolated antibody comprising an antigen binding region that specifically binds to human V-domain Ig Suppressor of T cell Activation (human VISTA), wherein the antibody agonizes or promotes the effects of VISTA on T cell immunity, and further wherein the antibody comprises a variable heavy chain which comprises heavy chain CDR1, CDR2 and CDR3 polypeptides having the sequences of SEQ ID NO: 740, 741 and 742 respectively and further comprises a variable light chain which comprises the light chain CDR1, CDR2 and CDR3 polypeptides having the sequences of SEQ ID NO: 743, 744 and 745 respectively, and wherein the antibody comprises a full length human IgG2 Fc region that comprises native binding to human Fc gamma receptors.